OptimizeRx Named America’s Fastest-Growing Company for Fifth Year in a Row
- OptimizeRx Corp. ranks 253 on the 2024 Financial Times’ Americas’ Fastest-Growing Companies list for the fifth consecutive year.
- The Company achieved 36% revenue growth between 2019 and 2022, fueled by a 'land and expand' strategy.
- OptimizeRx's growth is attributed to new life sciences clients, expanded offerings like the RWD.AI solution (now DAAP), and support for new branded medications.
- The market's strong adoption of DAAP, an AI-enabled platform, enhances healthcare engagement by predicting treatment eligibility and enabling earlier brand outreach.
- OptimizeRx CEO, Will Febbo, highlights DAAP's potential to improve patient outcomes, streamline healthcare delivery, and drive positive change in the industry.
- None.
Market Embraces Disruptive AI-Powered Capabilities
WALTHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, has secured a coveted spot on the 2024 Financial Times’ Americas’ Fastest-Growing Companies list for a remarkable fifth consecutive year, ranking at 253.
The Americas’ Fastest Growing Companies 2024 ranking identifies companies with the strongest revenue growth between the years 2019 and 2022. OptimizeRx’s
Market Embraces Disruptive DAAP Platform
OptimizeRx's impressive growth trajectory is further fueled by the market's strong adoption of its proprietary Dynamic Audience Activation Platform (DAAP). The AI (Artificial Intelligence)-enabled platform delivers predictive and privacy-safe marketing solutions, designed to connect life sciences, HCPs, and patients across the most robust network of personal and clinical platforms.
DAAP serves as a single source for life sciences organizations seeking to enhance the reach and effectiveness of their HCP and DTC healthcare marketing efforts. This robust platform positions OptimizeRx as a clear leader in data-driven healthcare engagement.
Leveraging real-world data and predictive modeling-empowered algorithms, DAAP compliantly predicts the time window when a patient becomes eligible for specific treatments, enabling earlier brand outreach and treatment initiation. This translates to significant revenue growth potential for life science partners.
"This five-year streak on the Financial Times list is a powerful signal of the market demand for our innovative capabilities," said Will Febbo, OptimizeRx CEO." Our newest enhancement, DAAP, has the potential to significantly improve patient outcomes by enabling earlier treatment initiation while streamlining healthcare delivery. This translates to a win-win scenario for both patients and the healthcare system, solidifying OptimizeRx's position as a leader in driving positive change within the industry."
OptimizeRx remains dedicated to pushing healthcare boundaries through continuous DAAP development. This commitment positions the Company to empower HCPs, optimize care delivery, and shape a healthier future for all.
About the FT Ranking
The Americas’ Fastest Growing Companies 2024 ranking identifies companies with the strongest revenue growth between the years 2019 and 2022. The creation of the ranking was based on a four-step process:
Application Phase: More than 30,000 eligible companies were invited to register. Only companies that met the criteria could apply for the ranking.
Research Phase: Statista examined the officially stated revenue data of over 1000 publicly listed companies in the Americas, and added high-profile companies that met the criteria of minimum revenues, independence, and organic growth to the list.
Evaluation Phase: The compound annual growth rate was calculated based on the revenue figures submitted and verified by the companies.
Ranking: The top 500 companies that met the criteria were ranked.
About OptimizeRx
OptimizeRx provides best-in-class health technology that enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. Connecting over 2 million U.S. healthcare providers and millions of their patients through an intelligent technology platform embedded within a proprietary digital point-of-care network, as well as mass digital communication channels, OptimizeRx helps life sciences organizations engage and support their customers.
For more information, follow the Company on Twitter, LinkedIn or visit www.optimizerx.com.
Important Cautions Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “estimates,” “expects,” “forecasts,” “intends,” “plans,” “projects,” “targets,” “designed,” “could,” “may,” “should,” “will” or other similar words and expressions are intended to identify these forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the Company’s growth, business plans, future performance, expected revenues, expected Adjusted EBITDA, expected adjusted EBITDA margin and prospects. These forward-looking statements are based on the Company’s current expectations and assumptions regarding the Company’s business, the economy, and other future conditions. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except as required by applicable law. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, any synergies and other anticipated benefits of the Medicx merger may not be realized or may take longer than anticipated to be realized; the risk that the integration of OptimizeRx and Medicx will be more costly or difficult than expected; the effect of government regulation, competition, and other risks summarized in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, its subsequent Quarterly Reports on Form 10-Q, and its other filings with the Securities and Exchange Commission.
OptimizeRx Contact:
Andy D’Silva, SVP Corporate Finance
adsilva@optimizerx.com
Media Relations Contact
Dilma Bennett, Media Relations Manager
dbennett@optimizerx.com
Investor Relations Contact
Ashley Robinson
LifeSci Advisors, LLC
arr@lifesciadvisors.com
FAQ
What ranking did OptimizeRx Corp. achieve on the 2024 Financial Times’ Americas’ Fastest-Growing Companies list?
What fueled OptimizeRx's revenue growth between 2019 and 2022?
What is the key feature of OptimizeRx's Dynamic Audience Activation Platform (DAAP)?
How does OptimizeRx CEO, Will Febbo, describe the potential of DAAP?
